CD180 Overexpression in Follicular Lymphoma

Completed

• Conditions: Follicular Lymphoma

• Registration Number: NCT02978898
• Lead Sponsor: Hospices Civils de Lyon

Brief Summary

Background:Altered Toll-like receptor (TLR) expression levels and/or mutations in its signaling pathway (such as MyD88 mutation) contribute to the pathogenesis of lymphoproliferative disorders (LPD). CD180 is an orphan member of the TLR family that modulates the signaling of several TLRs, but only limited studies have evaluated its expression by flow cytometry (FCM) in LPD.

Methods: Using a multiparameter FCM approach, biologists have assessed CD180 mean fluorescence intensity (MFI) in lymph nodes (LNs) and peripheral blood (PB) samples obtained from patients with follicular lymphoma (FL; LN/PB, n=44/n=15), chronic lymphocytic leukemia (CLL, n=26/n=21), mantle cell lymphoma (MCL, n=13/n=17), and marginal zone lymphoma (MZL, n=16/n=12). Specimens from non-tumoral PB and LN (n=8/n=12) were used as controls.

Detailed Description

Not available

Study Timeline

• Study Start: 2012-06
• Primary Completion: 2014-06
• Study Completion: 2015-06
• Status Verified: 2016-08
• Study First Submitted: 2016-08-29
• Study First Submitted QC: 2016-11-29
• Last Update Submitted: 2016-11-29
• Study First Posted: 2016-12-01
• Last Update Posted: 2016-12-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 184

Inclusion Criteria

• Samples from patients with:

  • LF: Follicular lymphoma
  • MCL: Mantle cell lymphoma
  • CLL/SLL: chronic lymphocytic leukemia/small lymphocytic leukemia
  • MZL : splenic marginal zone
  • Clt :control B-cells

Read More

Exclusion Criteria

• Patient <18 years old

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Immunophenotype Analysis by Flow Cytometry of peripheral blood samples at inclusion	At inclusion, day 0.	Using a multiparameter FCM approach, biologists assessed the CD180 expression by our routine antigen panel in LN suspensions as well as in PB samples. Samples were analyzed on a BD FACSCanto II cytometer (BD FACS DIVA software; Becton Dickinson, San Jose, CA).
Immunophenotype Analysis by Flow Cytometry of lymph nodes samples at inclusion	At inclusion, day 0.	Using a multiparameter FCM approach, biologists assessed the CD180 expression by our routine antigen panel in LN suspensions as well as in PB samples. Samples were analyzed on a BD FACSCanto II cytometer (BD FACS DIVA software; Becton Dickinson, San Jose, CA).